Last reviewed · How we verify

Nalmefene HCl injection

Leiden University Medical Center · FDA-approved active Small molecule

Nalmefene HCl injection is a Opioid receptor antagonist Small molecule drug developed by Leiden University Medical Center. It is currently FDA-approved for Opioid overdose reversal, Opioid dependence management. Also known as: Nalmefene IV, Nalmefene, Nalmefene hydrochloride, Nalmefene HCl.

Nalmefene is a competitive opioid receptor antagonist that blocks the effects of opioids by binding to opioid receptors with high affinity and specificity.

Nalmefene is a competitive opioid receptor antagonist that blocks the effects of opioids by binding to opioid receptors in the central nervous system. Used for Opioid overdose reversal, Opioid dependence management.

At a glance

Generic nameNalmefene HCl injection
Also known asNalmefene IV, Nalmefene, Nalmefene hydrochloride, Nalmefene HCl
SponsorLeiden University Medical Center
Drug classOpioid receptor antagonist
TargetMu, delta, and kappa opioid receptors
ModalitySmall molecule
Therapeutic areaAddiction Medicine / Emergency Medicine
PhaseFDA-approved

Mechanism of action

Nalmefene competitively antagonizes mu, delta, and kappa opioid receptors, preventing opioid agonists from binding and exerting their effects. It has a longer duration of action and higher receptor binding affinity compared to naloxone, making it suitable for both acute opioid overdose reversal and longer-term opioid dependence management. The drug rapidly displaces opioids from receptor sites, reversing respiratory depression and other opioid effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Nalmefene HCl injection

What is Nalmefene HCl injection?

Nalmefene HCl injection is a Opioid receptor antagonist drug developed by Leiden University Medical Center, indicated for Opioid overdose reversal, Opioid dependence management.

How does Nalmefene HCl injection work?

Nalmefene is a competitive opioid receptor antagonist that blocks the effects of opioids by binding to opioid receptors with high affinity and specificity.

What is Nalmefene HCl injection used for?

Nalmefene HCl injection is indicated for Opioid overdose reversal, Opioid dependence management.

Who makes Nalmefene HCl injection?

Nalmefene HCl injection is developed and marketed by Leiden University Medical Center (see full Leiden University Medical Center pipeline at /company/leiden-university-medical-center).

Is Nalmefene HCl injection also known as anything else?

Nalmefene HCl injection is also known as Nalmefene IV, Nalmefene, Nalmefene hydrochloride, Nalmefene HCl.

What drug class is Nalmefene HCl injection in?

Nalmefene HCl injection belongs to the Opioid receptor antagonist class. See all Opioid receptor antagonist drugs at /class/opioid-receptor-antagonist.

What development phase is Nalmefene HCl injection in?

Nalmefene HCl injection is FDA-approved (marketed).

What are the side effects of Nalmefene HCl injection?

Common side effects of Nalmefene HCl injection include Withdrawal symptoms (in opioid-dependent patients), Nausea, Headache, Tachycardia, Hypertension.

What does Nalmefene HCl injection target?

Nalmefene HCl injection targets Mu, delta, and kappa opioid receptors and is a Opioid receptor antagonist.

Related